Therapeutic targeting of triple-negative breast cancer: A multi-model evaluation of LNA-anti-miR-19b-3p and small molecule inhibitors
- 15 July 2025
- journal article
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 196 (Pt A) , 110771
Abstract
No abstract availableKeywords
Funding Information
- Babol University of Medical Sciences (140014011)
This publication has 32 references indexed in Scilit:
- Locked nucleic acid (LNA): A modern approach to cancer diagnosis and treatmentExperimental Cell Research, 2022
- Culture of Adherent Cancer Cell Lines2022
- MYPT1, regulated by miR-19b-3p inhibits the progression of non-small cell lung cancer via inhibiting the activation of wnt/β-catenin signalingLife Sciences, 2021
- MicroRNAs and gene regulation in breast cancerJournal of Biochemical and Molecular Toxicology, 2020
- Over expressing miR-19b-1 suppress breast cancer growth by inhibiting tumor microenvironment induced angiogenesisThe International Journal of Biochemistry & Cell Biology, 2018
- Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer2018
- Locked nucleic acid: modality, diversity, and drug discoveryDrug Discovery Today, 2018
- PDBsum: Structural summaries of PDB entriesProtein Science, 2017
- Current Status and Perspectives Regarding LNA‐Anti‐miR Oligonucleotides and microRNA miR‐21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal CancerJournal of Cellular Biochemistry, 2017
- Determination of apoptotic and necrotic cell death in vitro and in vivoMethods, 2013